AGENUS
Agenus develops and commercializes immunotherapies and vaccines for cancer and infectious diseases. The company's treatment aims to stimulate the immune system to recognize and fight cancer cells. Its goal is to treat cancers with novel combinations utilizing its unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines, and adjuvants. In addition to a broad portfolio, the company has an accomplished team of scientists, novel technology platforms, and fully-integrated end-to-end capabilities from discovery to GMP manufacturing. It was established in 1994 and is headquartered in Lexington, Massachusetts.
AGENUS
Industry:
Biotechnology Medical Medical Device Therapeutics
Founded:
1994-01-01
Address:
Lexington, Massachusetts, United States
Country:
United States
Website Url:
http://www.agenusbio.com
Total Employee:
501+
Status:
Active
Contact:
(781)674-4400
Total Funding:
346.14 M USD
Technology used in webpage:
Domain Not Resolving ReCAPTCHA Cloudflare Hosting Cloudflare CDN CloudFront ASP.NET Ajax Google Analytics IP Anonymization Q4Web Hosting
Similar Organizations
Adaptimmune
Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
DNAnexus
DNAnexus develops a cloud platform and global network designed for scientific collaboration and accelerated discovery.
Evaxion Biotech
Evaxion Biotech is devoted to the discovery and development of vaccines against cancer and infectious diseases.
Haemonetics
Haemonetics is a provider of blood and plasma supplies and services.
Halozyme Therapeutics
Halozyme Therapeutics develops extracellular matrix targeting products for the insulin, cancer, dermatology and drug delivery markets.
Humacyte
Humacyte develops products for vascular diseases and replacement of anatomical conduits.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Sutro Biopharma
Sutro Biopharma develops protein therapeutics by using OCFS protein synthesis technology.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2015-12-27 | PhosImmune | PhosImmune acquired by Agenus | 44.9 M USD |
| 2015-04-08 | Celexion | Celexion acquired by Agenus | 4 M USD |
| 2014-01-13 | 4-Antibody AG | 4-Antibody AG acquired by Agenus | N/A |
Investors List
Ligand Pharmaceuticals
Ligand Pharmaceuticals investment in Post-IPO Debt - Agenus
Incyte
Incyte investment in Post-IPO Equity - Agenus
Iroquois Capital
Iroquois Capital investment in Post-IPO Equity - Agenus
Hudson Capital Group
Hudson Capital Group investment in Post-IPO Equity - Agenus
Downsview Capital
Downsview Capital investment in Post-IPO Equity - Agenus
Key Employee Changes
| Date | New article |
|---|---|
| 2023-07-20 | Agenus Expands Executive Leadership Team |
Official Site Inspections
http://www.agenusbio.com Semrush global rank: 2.41 M Semrush visits lastest month: 7.92 K
- Host name: 23.185.0.4
- IP address: 23.185.0.4
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Agenus"
Agenus - Wikipedia
Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or … See details»
Agenus - LinkedIn
Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations ... See details»
Agenus Inc. - Investor Relations
May 12, 2025 [email protected] Quick Links. SEC Filings; Information Request Form; Investor Email Alerts. To opt-in for investor email alerts, please enter your email address in the … See details»
Agenus - Crunchbase Company Profile & Funding
Organization. Agenus . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email … See details»
Agenus Announces Strategic Realignment to Focus on Core
Dec 5, 2024 About Agenus. Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a … See details»
Agenus Company Profile - Office Locations, Competitors, Revenue
Oct 29, 2024 Agenus has 5 employees across 5 locations and $103.46 m in annual revenue in FY 2024. See insights on Agenus including office locations, competitors, revenue, financials, … See details»
Team - Agenus
Dr. Garo Armen serves as Chairman and Chief Executive Officer of Agenus Inc., which he co-founded in 1994. Under his leadership, Agenus has been advancing breakthrough scientific technologies and immunotherapeutic products. See details»
Zydus to enter global biologics CDMO business: Plans to ... - Newswire
2 days ago For more details visit: www.agenusbio.com. Forward-Looking Statements: ... Organization Profile. Zydus Lifesciences. Contact Cision. 866-245-2317 from 8 AM - 10 PM ET … See details»
Zydus to enter global biologics CDMO business Plans to acquire …
1 day ago Leveraging proprietary scientific platforms, the company’s pipeline includes multiple checkpoint antibody candidates, vaccines, and cell therapies. Headquartered in Lexington, MA, … See details»
Zynext Ventures acquires stake in Agenus, expands its …
2 days ago /PRNewswire/ -- Zynext Ventures USA LLC (Zynext), the venture capital arm of Zydus Lifesciences (Zydus), today announced its investment in Agenus Inc., a... See details»
Zydus to enter global biologics CDMO business: Plans to ... - Nasdaq
2 days ago The acquisition will establish Zydus' presence in fast growing global biologics CDMO space. Acquired capabilities include cutting-edge biologics development and manufacturing … See details»
Agenus Prioritizes Resources to Accelerate Registration and ...
Aug 23, 2023 The plan will reduce operating expenses across Agenus' global organization by concentrating its quality, manufacturing, clinical, regulatory, and research & development … See details»
Agenus Announces Strategic Realignment to Focus on Core …
Dec 5, 2024 Investors 917-362-1370 [email protected]. Media 612-839-6748 [email protected]. Site Navigation. Home. Home; Submit a Press Release; … See details»
Press Release Details - investor.agenusbio.com
2 days ago $75M upfront payment to Agenus for the transfer of manufacturing assets $50M of contingent payments to Agenus Exclusive license for BOT/BAL in India and Sri Lanka $16M … See details»
Our History - Agenus
Agenus discovers, manufactures and develops immuno-oncology products. The company’s I-O portfolio is comprised of checkpoint antibodies, cell therapies, vaccines, and adjuvants, … See details»
Zydus to Enter Global Biologics CDMO Business Plans to Acquire …
2 days ago The acquisition will establish Zydus’ presence in fast growing global biologics CDMO space. Acquired capabilities include cutting-edge biologics development and manufacturing … See details»
Zydus to enter global biologics CDMO business: Plans to acquire …
2 days ago For more details visit: www.agenusbio.com. SOURCE: Zydus Lifesciences. Post Views: 15. ... referred to as ‘Zydus’ today announced its entry into the global biologics contract … See details»
Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration …
2 days ago Agenus Investors 917-362-1370 [email protected]. Agenus Media 781-674-4422 [email protected]. Company. About Business Wire Careers Media Center. … See details»
Agenus to Provide Corporate Update and First Quarter 2025
Apr 29, 2025 Agenus Inc., a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2025 financial results before … See details»
Patients & Care Partners - Agenus
To learn more about our clinical trials, patient advocacy initiatives or to discuss ways to collaborate, please contact us at: +1 781-384-2053 or [email protected]. Agenus Inc. 3 Forbes Road See details»